Research and Markets (http://www.researchandmarkets.com/research/fxrgl6/targeting_cell) has announced the addition of the "Targeting Cell Adhesion Molecules (CAMs) for the Treatment of Cancer Drug Pipeline Update 2015" report to their offering.
Cell adhesion molecules are (glyco)proteins expressed on the cell surface and play a critical role in a wide array of biologic processes that include hemostasis, the immune response, inflammation, embryogenesis, and development of neuronal tissue. There are four main groups: the integrin family, the immunoglobulin superfamily, selectins, and cadherins.
There are today 104 companies plus partners developing 106 targeting CAMs drugs in 330 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 47 drugs.
Targeting Cell Adhesion Molecules (Cams) For The Treatment Of Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 99 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 97 out of the 97 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 27 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 3
- Pre-registration - 1
- Phase III - 11
- Phase II - 33
- Phase I - 30
- Preclinical - 51
- No Data - 1
- Suspended - 2
- Ceased - 47
Delivery Format: Desktop App plus Online Access to Updates (One Year)
For more information visit http://www.researchandmarkets.com/research/fxrgl6/targeting_cell
